NOVOZYMES A/S SPONS.ADR 1 Capital Reinvestment Ratio
NOVOZYMES A/S SPONS.ADR 1 capital reinvestment ratio. NOVOZYMES A/S SPONS.ADR 1 (NZM) has a Capital Reinvestment Ratio of 0.56x as of March 2026, meaning it reinvests 1% of its operating cash flow (€167.10 Million) in capital expenditures (€93.10 Million). See NZM free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
Capital reinvestment ratio of NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025. This chart tracks NOVOZYMES A/S SPONS.ADR 1's Capital Reinvestment Ratio across 5 annual periods. See how financially flexible is NOVOZYMES A/S SPONS.ADR 1 to measure the company's free cash flow as a share of total liabilities.
NOVOZYMES A/S SPONS.ADR 1 Capital Reinvestment Ratio by Year (2021–2025)
NOVOZYMES A/S SPONS.ADR 1 capital reinvestment ratio by year from 2021 to 2025. For the full cash flow conversion analysis, see NOVOZYMES A/S SPONS.ADR 1 (NZM) cash conversion ratio.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.39x | €1.22 Billion | €470.80 Million | ▲ +9.3% |
| 2024 | 0.35x | €1.02 Billion | €359.80 Million | ▼ -28.7% |
| 2023 | 0.50x | €557.10 Million | €275.80 Million | ▼ -31.4% |
| 2022 | 0.72x | €537.65 Million | €387.87 Million | ▲ +136.3% |
| 2021 | 0.31x | €546.17 Million | €166.73 Million | — |